Related references
Note: Only part of the references are listed.Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program
Abdi T. Gudina et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics
Tithi Biswas et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)
Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
Waqar Haque et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes
Tina J. Hieken et al.
CLINICAL BREAST CANCER (2018)
Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database
Jieqiong Liu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers
Audrey Monneur et al.
ONCOTARGET (2017)
Inflammatory breast cancer in the Netherlands; improved survival over the last decades
D. J. P. van Uden et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment
Laura Orlando et al.
BREAST (2016)
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis
Tamer M. Fouad et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Inflammatory breast cancer: An overview
D. J. P. van Uden et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study
Xi Jin et al.
ONCOTARGET (2015)
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes
H. Masuda et al.
ANNALS OF ONCOLOGY (2014)
Incidence of Inflammatory Breast Cancer in Women, 1992-2009, United States
Bryan Goldner et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients
M. J. Engstrom et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
Susan Dent et al.
CANCER TREATMENT REVIEWS (2013)
Risk Factors for Inflammatory Breast Cancer and Other Invasive Breast Cancers
Catherine Schairer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Identifying factors that impact survival among women with inflammatory breast cancer
S. Dawood et al.
ANNALS OF ONCOLOGY (2012)
Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades
Reina Haque et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment
S. Dawood et al.
ANNALS OF ONCOLOGY (2011)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
TNM Seventh Edition: What's New, What's Changed Communication From the International Union Against Cancer and the American Joint Committee on Cancer
Leslie H. Sobin et al.
CANCER (2010)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Molecular heterogeneity of inflammatory breast cancer: A hyperproliferative phenotype
Dang M. Nguyen et al.
CLINICAL CANCER RESEARCH (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
